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Background. Second kidney transplantations have a roughly
similar clinical outcome to first transplantations. Nevertheless,
the effect of the presence of the first, nonfunctional transplant
at the time of the second transplantation may also influence its
outcome and has not yet been specifically studied.
Methods. We analyzed the effect of the presence of a first graft
on the outcome of a second graft in a rodent allograft model
and in a cohort of 240 human second kidney allograft recipients.
Results. In rodents, 100 days subsequent to the rejection of
the first graft, we observed an increase in blood but not spleen
CD4+CD25+ T cells, whereas no differences were observed in
transcriptional patterns. Adoptive transfer of day 100 spleno-
cytes did not prolong graft survival. Moreover, the presence
of a first rejected graft does not prolong the survival of a sec-
ond graft performed at a later date. In the human context, a
higher incidence of patients with anti-HLA immunization and
a higher % of PRA were observed in retransplant recipients
with primary allograft nephrectomy. Despite a relatively low
statistical power, our data do not suggest significant differences
in graft outcome between recipients of second transplants with
primary allograft nephrectomy and those without.
Conclusion. Collectively, the data from both an experimen-
tal model and a large cohort of human recipients of a second
graft do not suggest a beneficial effect of the presence of a first
rejected graft at the time of a second transplantation.
We have recently shown that second kidney transplants
have a similar outcome to first transplants when four
1and 2contributed similarly as first authors and senior investigators,
respectively.
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HLA antigen matching and a stringent cross match pol-
icy are observed [1]. However, the presence of a first,
nonfunctional transplant may influence the outcome of
a subsequent transplantation. Indeed, previous studies
have shown that the presence of a first transplant is as-
sociated with a lower incidence of panel reactive anti-
bodies (PRA) [2]. In contrast, graft removal is often fol-
lowed by a rise in anti-HLA antibodies, suggesting that
the presence of a nonfunctional graft may either regu-
late the capacity of the recipient to mount an immune
response to the donor’s major histocompatibility com-
plex antigens (MHC) or absorb a low level of antibodies
[3–5]. The effect of a first kidney graft on the outcome of
a second graft has not, however, been analyzed in detail.
In a study performed on 127 second kidney graft recip-
ients, Douzdjian et al [6] reported a lower incidence of
acute rejection following a second transplant in recipients
who still had their first graft, suggesting that some pro-
tective effects on the outcome of the second graft could
occur.
Such a possibility is also supported by experimental
studies performed in a rat model of chronic graft rejection
model showing that, in a minor histocompatibility anti-
gen mismatch combination (Fischer 344, RT11v1/LEW,
RT11), a state of unresponsiveness to a second transplant
is induced [7, 8]. However, in another study performed in
a MHC mismatch combination (Buff/LEW), only mod-
erate prolongation of a second graft was observed (≈10
days), and this modest effect was highly dependent on the
timing of the second transplantation, which had to be per-
formed within a week following the rejection of the first
[9]. Furthermore, recent observations in mice suggest that
CD25-positive (CD25+) regulatory T-cells may be up-
regulated by inflammatory processes. For instance, Cara-
malho et al showed that regulatory T-cells could control
adverse or inappropriate immune responses to pathogens
in mice [10]. Taken together, these observations suggest
that, besides the obvious initial effects of a transplant on
the host immune response, which results in an early acute
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rejection, the persisting presence of alloantigens may trig-
ger regulatory processes. Such processes may be able to
influence the host response to a subsequent graft, thus
leading to a lower incidence of (or delayed) rejection.
In this paper, we analyzed the effect of the presence of
the first graft on the outcome of a subsequent graft in a
rodent model of cardiac allotransplantation, as well as in a
series of 240 consecutive second kidney allotransplants in
humans. We showed that in both the experimental model
and the clinical setting, the presence of a first graft did not
overtly influence the outcome of a second graft. These
data, which address both theoretical and clinical issues,
are discussed.
METHODS
Animals and cardiac allotransplantation
Eight-week-old male LEW.1W and LEW.1A rats
weighing 250 g were purchased from Janvier (Savigny/
Orge, France). These rat strains are congeneic and dif-
fered in their MHC haplotype: the LEW.1W rats were
RT1u and the LEW.1A rats were RT1a. All animals
were maintained under standard conditions according to
European and Institutional Guidelines. LEW.1A rats
were used as recipients of heterotopic cardiac transplants,
performed as described [11]. Graft function was evalu-
ated daily by abdominal palpation, and rejection was de-
fined as the day of cessation of heart beating. LEW.1A
recipients that had rejected a first LEW.1W graft received
a second LEW.1W heart 100 days after the initial trans-
plantation (D100).
Adoptive cell transfer experiments
One hundred days after the initial transplantation,
spleen cells were harvested from LEW.1A recipients that
had rejected a LEW.1W heart. Spleen cells depleted of
erythrocytes were then either injected I.V. in transfer
experiments or used for T cell purification. Blood was
collected on EDTA by cardiac puncture, and peripheral
blood mononuclear cells (PBMC) were separated on a
density gradient (ficoll, Amersham Biosciences, Uppsala,
Sweden). T cells were purified using Rat T cell enrich-
ment columns (R&D Systems, Minneapolis, MN, USA).
Purity was assessed by flow cytometry (>94%). Adoptive
transfers were performed on the day of the transplanta-
tion of a LEW.1W heart into a secondary LEW.1A recip-
ient treated with 4.5 Gy whole body irradiation before
transplantation.
Flow cytometric analysis
Cell suspensions were incubated for 30 minutes at
room temperature with the following fluoroscein isoth-
iocyanate (FITC)-conjugated antibodies: W3/25 (anti-
CD4), OX8 (anti-CD8), 3.2.3 (anti-NK) (all from Serotec
Table 1. Primer sequences for cytokine transcript analysis for PCR
Cytokine Primer sequences
IFNc sense 5′-CAGCTCTGCCTCATGGCC-3′
IFNc antisense 5′-GATTCTGGTGACAGCTGGTG-3′
IL-13 sense 5′-AGCAACATCACACAAGACCAG-3′
IL-13 antisense 5′-CACAACTGAGGTCCACAGCT-3′
TGF-ß1 sense 5′-CTACTGCTTCAGCTCCACAG-3′
TGF-ß1 antisense 5′-TGCACTTGCAGGAGCGCAC-3′
TNFa sense 5′-CCTTACGGAACCCCCTATATT-3′
TNFa antisense 5′-GACCCGTAGGGCGATTACAG-3′
IL-10 sense 5′-TCAGCACTGCTATGTTGCC–3′
IL-10 antisense 5′-CCTTGCTTTTATTCTCAGAGG -3′
IL-2 sense 5′-CCTTGTCAACAGCGCACCC-3′
IL-2 antisense 5′-GCTTTGACAGATGGCTATCC-3′
HPRT sense 5′-TGCTGGATTACATTAAAGCGC-3′
HPRT antisense 5′-CTTGGCTTTTCCACTTCGC-3′
The results were expressed as the intrasample ratio of cytokine/HPRT mRNA
copy numbers.
Laboratories, Oxford, UK), and the following biotiny-
lated antibodies: R7−3 (anti-TCRab), Ox39 (anti-CD25
a chain) (from Bioatlantic, Nantes, France), and revealed
by Streptavidine-PE (Immunotech, Beckman Coulter,
Marseille, France). Cells were washed twice in phosphate-
buffered saline (PBS) and double-color staining analyzed
by a FACSCalibur using Cellquest Pro software (BD
Biosciences, Mountain View, CA, USA).
Cytokine transcript analysis
Cytokine transcript analysis was performed using real-
time quantitative polymerase chain reaction (PCR) for
IL2, IFNc, IL13, TGFb1, IL10 and TNFa. Briefly, a con-
stant amount of cDNA was amplified in 25 lL of 10X
SYBR Green PCR Core Reagent (Perkin-Elmer Ap-
plied Biosystems, Foster City, CA, USA). Amplifications
were performed in an ABI Prism 7900-Perkin Elmer
Sequence Detection system (Perkin-Elmer Applied
Biosystems). The exact number of copies of the target
cDNA sequence was deduced by comparing the mea-
sured fluorescence with a standard curve and was stan-
dardized against the level of HPRT transcripts. The
primer sequences are displayed in Table 1.
Patients
Among 1513 consecutive cadaver kidney transplan-
tations performed in adults at our institution between
January 1990 and December 2002, 240 (16%) were second
grafts. Of these second transplant recipients, 83 (34.6%)
patients had undergone nephrectomy of the primary al-
lograft (group I) and 157 had not (group II). Indications
for transplant intracapsular nephrectomy included unex-
plained fever, graft pain or tenderness, persistent hema-
turia, graft infection, or uncontrolled hypertension [12].
While the patients were on the transplant waiting list,
their serum was tested for the presence of anti-HLA
antibodies systematically two and three weeks after the
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first transplant nephrectomy, after every blood transfu-
sion, and every three months systematically thereafter.
Anti-HLA antibodies were detected by complement-
dependent cytotoxicity assay performed on B and T cells
separately on a panel of 36 representative HLA-typed
donors [13]. The second transplant matching policy re-
quired a minimum of four HLA compatibilities, with pri-
ority given to patients with high levels of panel reactive
antibodies (PRA) [1]. Repeated HLA mismatches were
only allowed when the recipient had not developed anti-
HLA class I or anti-class II antibodies specific for the sec-
ond donor’s lymphocytes. The pretransplant crossmatch
was performed by complement-dependent cytotoxicity
according to NIH guidelines. The T-cell crossmatch on
historic as well as current sera had to be negative. How-
ever, a positive crossmatch on B cells, without antidonor
T reactivity, was not considered as a contraindication to
transplantation [14]. As autoantibodies are generally of
the IgM isotype, the crossmatch was also carried out in the
presence of dithiothreitol to discriminate between IgM
and IgG antibodies.
Immunosuppressive protocol
All patients were treated according to the same
quadruple sequential immunosuppressive protocol, con-
sisting of an induction therapy, delayed introduction of
a calcineurin inhibitor, and a “standard” maintenance
therapy. Induction therapy consisted of polyclonal anti-
lymphocyte preparations (rabbit ATG) at a dose of
1 mg/kg/day (IMTIX-SangStat, Lyon, France) admin-
istered in the immediate post-transplant period for 10
to 14 days, and associated with azathioprine (Imurel,
Glaxo Smith Kline, Marly-Le-Roy, France) (2 mg/kg/day)
or mycophenolate mofetil (Cellcept, Roche, Neuilly-
sur-Seine, France) (2 g/day) and corticosteroids (pred-
nisone, Cortancyl, Aventis, Paris, France) at a dose
of 1 mg/kg/day. Cyclosporine (Sandimmun or Neo-
ral, Novartis Pharma SA, Rueil-Malmaison, France) or
tacrolimus (Prograf, Fujisawa, La Celle-Saint-Cloud,
France) was begun one day before the end of induc-
tion therapy at a dose of 8 mg/kg/day or 0.1 mg/kg/day,
respectively. The anticalcineurin regimen was adjusted
to maintain trough levels of 150 to 250 ng/mL for cy-
closporine and 10 to 15 ng/mL for tacrolimus. The pred-
nisone dose was decreased 10 mg every five days to a
maintenance dose of 10 mg/day, and slowly tapered af-
ter three months. Biopsy-confirmed AR episodes were
treated with intravenous boluses of methylprednisolone
for five consecutive days (5 mg/kg/day for two days, ta-
pered by 1 mg/kg/day every day), followed by decreasing
doses of oral prednisone. ATG or antilymphocyte mon-
oclonal OKT3 antibody was used in the case of corticos-
teroid unresponsiveness or severe rejections (Banff grade
II or III).
Data bank and statistical analysis
The clinical data were obtained from a computer-
ized and validated standard database called the “DI-
VAT network” (Donne´es Informatise´es et VAlide´es en
Transplantation) [1, 15]. In this procedure, a special-
ized clinical research assistant, who is independent of the
medical team, prospectively collects the pre- and post-
transplant data of all patients transplanted at our insti-
tution. The database is validated annually by a medical
audit and has an error level below 1%. The database in-
cludes demographic characteristics (age, donor and re-
cipient gender), immunologic parameters [anti-T and -B
peak PRA, HLA-A, -B, -DR mismatch (MM)], and trans-
plant variables [serum creatinine and daily proteinuria
until 12 months, cold ischemia time, delayed graft func-
tion (DGF) and AR]. Return to a chronic dialysis pro-
gram or death with a functioning graft was considered
as a graft loss. The immunosuppressive treatment was
stopped within the first month after dialysis onset. AR
was identified by standard clinical criteria in conjunction
with a renal biopsy (except if contraindicated) analyzed
according to the Banff classification. DGF was defined as
the need for at least one dialysis session during the first
seven days after transplantation, and/or the number of
days required to reach a Cockcroft-calculated creatinine
clearance of at least 10 mL/min [16]. Graft and patient
survival analysis was performed using the Kaplan-Meier
method, followed by log-rank analysis. Baseline charac-
teristics among groups were compared using a chi-square
test and analysis of variance (ANOVA) for categorical
and continuous variables. A P value < 0.05 was consid-
ered significant.
RESULTS
Animal study
Phenotype and transcriptional patterns of recipients that
had rejected a ﬁrst graft, analyzed 100 days after the initial
transplantation. The phenotype of spleen and blood T
cells was first examined 100 days after transplantation in
LEW.1A recipients that had rejected a first graft (N = 5),
and was compared to age-matched naive LEW.1A rats. In
the spleen, no variation in CD4+ and CD8+ T cells were
apparent, and CD25+ T cells were also at roughly similar
levels in recipients that had rejected a first graft (N = 5,
16 ± 8%) or naive LEW.1A (N = 5, 12 ± 4%, ns). In naive
rats, 11 ± 4% of the CD4+ cells were CD25+ compared to
17 ± 7% (ns) in recipients that had rejected a first graft.
The percentage of CD8+CD25+ spleen cells was similar
in the two groups (2.8 ± 0.6%, 3.5 ± 2%, respectively).
In the blood, CD25+ T cells were, however, significantly
increased in recipients that had rejected their first graft
and tested on day 100 (16.5 ± 4%, N = 5) compared to
naive LEW.1A rats (7 ± 3%, N = 5, P < 0.05). Blood
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CD4+CD25+ were found to be 10.5 ± 3.8% (N = 5) ver-
sus 3.4 ± 1% in normal rats (N = 4) (P < 0.01), but no
differences were observed for CD8+CD25+ cells.
We next analyzed IL2, IFNc, IL13, TGFb1, IL6, TNFa,
and IL10 spleen and blood transcript accumulation by
real-time PCR in day 100 LEW.1A recipients that had
rejected a first LEW.1W graft and in naive LEW.1A rats.
No difference was observed for the spleen or the blood
(in terms of the cytokine/HPRT transcript ratios). How-
ever there was a nonsignificant trend toward a lower ac-
cumulation of IL2 transcripts (91.10−3 ± 64.10−3, N = 5
versus 172.10−3 ± 130.10−3, N = 5) in recipients that had
rejected a first graft.
Taken together, these data show that recipients that
had rejected a first graft had an increased pool of cir-
culating CD4+ CD25+ cells. The fact that we also ob-
served a down-regulation of IL2 transcripts in blood T
cells suggest that these CD25+ cells could be regulatory
cells, rather than memory alloreactive cells. For these rea-
sons, we next analyzed the survival of a second LEW.1W
heart and the effect of the transfer of cells from rats that
had rejected a first graft 100 days previously into a naive
secondary LEW.1A recipient.
Long-term untreated LEW.1A recipients that initially
reject a LEW.1W heart graft do not accept a second
LEW.1W heart graft, and do not harbor regulatory cells
able to prolong the survival of LEW.1W hearts in naive
LEW.1A rats. Unmodified LEW.1A rat recipients re-
jected a MHC incompatible LEW.1W heart graft within
6.5 ± 0.6 days. A second LEW.1W transplant performed
100 days after rejection of the first graft was subject to re-
jection within 8 ± 1.8 days (N = 3) (Fig. 1). Splenocytes
or PBMC of naive LEW.1A rats or of day 100 LEW.1A
recipients that had initially rejected a first LEW.1W graft
were then administered to subirradiated LEW.1A sec-
ondary recipients of a LEW.1W heart graft on the day of
transplantation. Control subirradiated LEW.1A recipi-
ents, without further treatment, rejected their heart grafts
within 16 ± 3 days (N = 11). The adoptive transfer of 100
± 106 splenocytes from either naive or day 100 LEW.1A
recipients that had initially rejected a first LEW.1W graft
had no effect on graft survival (N = 3, 15 ± 2). Further-
more, the adoptive transfer of 20 × 106 PBMC from re-
cipients who had rejected a first graft did not increase but
rather shortened graft survival (N = 3, 9 ± 3 days).
Clinical study
Patient population and pre- and post-transplant im-
munologic characteristics. Recipients of a second renal
allograft were divided into two groups: group I (N = 83),
which had undergone primary allograft nephrectomy, and
group II (N = 157), which had not. The demographic
characteristics of the two groups were not significantly
different (Table 2). The mean donor and recipient age
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Fig. 1. Survival of second LEW.1W allografts in transplanted LEW.
1A recipients that had rejected a first graft, 100 days after the first
transplantation.
Table 2. Demographic characteristics and the immunosuppressive
regimen of group I (N = 83, with first graft nephrectomy) and group
II (N = 157, without nephrectomy)
Demographic characteristics and Group I Group II
immunosuppressive regimen (N = 83) (N = 157)
Recipient age years
Mean ± SD 43.6 ± 12 42.6 ± 13
Range 20–71 16–73
Recipient sex [N (%)]
Male 50 (60%) 105 (67%)
Donor age years
Mean ± SD 36.4 ± 15 39.6 ± 14
Range 9–68 6–72
Donor sex [N (%)]
Male 57 (69%) 113 (72%)
Year of transplantation [N (%)]
1990 to 1995 37 (44.6%) 53 (33.8%)
1996 to 2002 46 (55.4%) 104 (66.2%)
Renal disease [N (%)]
Glomerulonephritis 41 (49.4%) 67 (42.7%)
Hereditary 22 (26.5%) 29 (18.5%)
Tubulointerstitial 11 (13.3%) 33 (21%)
Diabetes 2 (2.4%) 10 (6.4%)
Hypertension, vascular 4 (4.8%) 4 (2.5%)
Other, unknown 3 (3.6%) 14 (8.9%)
Hypertension [N (%)]
Yes 46 (55.4%) 85 (54.1%)
No 37 (44.6%) 72 (45.9%)
Immunosuppressive regimen [N (%)]
Cyclosporine, Sandimmun 44 (53%) 59 (37.6%)
Cyclosporine, Neoral 6 (7.2%) 22 (14%)
Tacrolimus 33 (39.8%) 76 (48.4%)
Azathioprine 41 (49.4%) 59 (37.6%)
Mycophenolate mofetil 42 (50.6%) 98 (62.4%)
and sex ratios, the rate of hypertension, the etiology of
the original kidney disease, and the year of transplanta-
tion were similar. The characteristics of the immunosup-
pressive treatments did not differ between the two groups
(Table 2).
No statistical difference was observed between the two
groups in terms of one-year serum creatinine, daily pro-
teinuria, cold ischemia time, and DGF (Table 3). The inci-
dence of AR was also similar (17% for group I vs. 14% for
group II). The global HLA or HLA-A/B/DR mismatch
was not significantly different between the two groups:
72.3% of patients who had undergone primary allograft
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Table 3. Allograft function in the patients of group I (N = 83, first
graft nephrectomy) and II (N = 157, without nephrectomy) and the
incidence of acute rejection episodes
Group I Group II
Graft characteristics (N = 83) (N = 157)
Serum creatinine at 12 months lmol/L
Mean ± SD 136 ± 51 144 ± 95
Range 67–282 59–979
Proteinuria at 12 months g/24hr
Mean ± SD 0.30 ± 0.31 0.49 ± 1.07
Range 0–1.45 0–7.85
Cold ischemia time hours
Mean ± SD 30 ± 9.4 29 ± 9.4
Range 10.8–50 9.5–50
DGF
Mean ± SD of days with Cl. ≥10 mL/mina 8 ± 7.5 6.7 ± 6
First graft dialysis sessiona Mean ± SD 1.56 ± 2.26 1.48 ± 1.91
AR episodes [N (%)] 14 (17%) 22 (14%)
Cl., creatinine clearance.
aSee Methods section.
Table 4. Immunologic parameters of group I (N = 83, with first graft
nephrectomy) and group II (N = 157, without nephrectomy)
Group I Group II
Immunologic parameters (N = 83) (N = 157)
Peak PRA [(% ± SD)]
anti-T 43% ± 37a 33% ± 36a
anti-B 51% ± 32 45% ± 32
PRA [n (%)]
anti-T ≤25% 35 (42.2%)b 89 (56.7%)b
anti-T ≥25% and <80% 27 (32.5%) 39 (25%)
anti-T ≥80% 21 (25.3%) 29 (18.3%)
Global HLA MM [N (%)]
≤2 60 (72.3%) 112 (71.3%)
>2 23 (27.7%) 45 (28.7%)
HLA-A MM [N (%)]
0 41 (49.4%) 72 (45.9%)
1 36 (43.4%) 72 (45.9%)
2 6 (7.2%) 13 (8.2%)
HLA-B MM [N (%)]
0 25 (30.1%) 47 (30%)
1 45 (54.2%) 92 (58.6%)
2 13 (15.7%) 18 (11.4%)
HLA-DR MM [N (%)]
0 47 (56.6%) 84 (53.5%)
1 34 (41%) 64 (40.8%)
2 2 (2.4%) 9 (5.7%)
aP = 0.048, ANOVA.
bP < 0.05, chi-square.
nephrectomy received a well-matched kidney (HLA MM
≤2) versus 71.3% of patients who had not undergone this
procedure. Likewise, recipients were identically matched
for HLA-DR. In particular, 56.6% of group I recipients
versus 53.5% of group II patients had no HLA-DR mis-
match (Table 4).
However, the retransplanted patients in group I were
characterized by higher anti-HLA levels. In addition, the
PRA peak occurred between the two transplantations
for the majority of the immunized patients (anti-T PRA
≥25% for 91% of group I patients vs. 88% of group II
patients). Moreover, 82% of immunized patients in the
transplantectomy group exhibited a rise in their PRA lev-
els within the first six months following surgery. Anti-T
cell PRA peak was also significantly higher in group I
(43%) than in group II (33%) (P = 0.048). No difference
was observed for anti-B cell PRA. Finally, the percentage
of recipients with a low level of anti-HLA immunization
(anti-T PRA <25%) was significantly lower in the group
of patients who had undergone nephrectomy (Table 4).
Incidence of graft survival and rejection. Recipients of
a second transplant that had or had not undergone pri-
mary allograft nephrectomy showed no significant differ-
ences (see Fig. 2) in graft survival. Similar results were
obtained when patient death was censored (data not
shown). According to Kaplan-Meier analysis, graft sur-
vival was 92%, 81%, and 62% at 1, 5, and 10 years, re-
spectively, for group I, and 92%, 79%, and 65% at 1, 5, and
10 years, respectively, for group II. Among the causes of
secondary transplant loss, death with a functioning graft
accounted for 19% versus 25%, AR for 14.3% versus
12.5%, chronic rejection for 42.8% versus 30%, vascular
and recurrent renal disease for 23.8% versus 32.5%, for
group I and group II, respectively. When immunologic
causes of transplant failure were examined separately or
together, there was no statistical difference between the
two groups.
DISCUSSION
In rodents, some reports have suggested that recipients
of a first heart allograft that is mismatched in terms of mi-
nor histocompatibility antigens who undergo rejection,
but in whom the rejected organ is not removed, can de-
velop mechanisms able to prolong the survival of a second
graft [7]. Of course, the rat model does not entirely con-
form with the human situation. Indeed, in the rat model,
a second graft from the same donor strain reintroduces
the original donor antigens, which may lead to the in-
duction of donor-specific regulatory cells. However, the
transplantation of a third party graft, thus mimicking the
human situation, is not influenced by priming with anti-
gens of another strain [17]. In addition, a heart model
was used because a life-sustaining kidney model would
have required the presence of the recipient’s own kidney
in the long term. Moreover, in this combination, about
15% of kidney transplants are spontaneously accepted, a
phenomenon which cannot be detected in the presence
of a native kidney.
In an MHC-mismatched combination, the effect of re-
transplantation was shown to be a modest and restricted
to a limited time window after transplantation [9]. Be-
cause only a few studies have explored the effects of the
presence of a first rejected graft on the survival of a second
graft in human recipients, and because retransplantation
is now a routine procedure in humans (≈25%) and is as-
sociated with favorable survival [1], the possibility that
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Fig. 2. Long-term graft survival for retransplantations with (group I) or without (group II) primary allograft nephrectomy (A). Serum creatinine
(mean and median), with the number of patients remaining under observation (in brackets) at 12, 60, and 120 months in each group (B).
a first graft could induce a regulation of the alloimmune
response to a subsequent graft, thereby contributing to
this good outcome, needs to be considered. Furthermore,
among the few clinical studies [2, 18, 6] that have ad-
dressed the rationale of first graft removal and its effects
on the outcome of a second graft, two reported a lower
incidence of rejection episodes in recipients that still had
their graft in place, although this point was not detailed
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[2, 6]. Another report mentioned a significantly lower
graft survival when the first kidney was removed [18].
Interestingly, all these studies reported a lower level of
PRA when the first transplant was not removed.
Our data show that rat recipients of a first MHC-
mismatched graft exhibit some increase in circulating
CD25+ and CD4+CD25+ T cells in the blood, but not
in the spleen. The fact that this augmentation was not
associated with an increase in IL2 transcript levels could
suggest the presence of regulatory T cells in these animals.
However, this hypothesis was not confirmed by: (1) the
short survival of a second graft from the original donor
strain, and (2) the absence of graft survival prolongation
following transfer of splenocytes from day 100 recipients
having rejected a first graft to naive hosts. Both points also
challenge the possibility of the differentiation of a sub-
population of T or non-T regulatory cells. Importantly, in
this same strain combination, the transfer of 100 × 106
splenocytes from recipients treated with a donor-specific
blood transfusion-induced tolerance protocol (Lair et al,
in preparation), or a deoxyspergualine-induced tolerance
protocol [19], consistently results in long-term survival.
Therefore, despite the fact that rat recipients of a fully
MHC incompatible graft may exhibit some delay in the
rejection of a donor-matched subsequent graft in a lim-
ited time period following rejection of the first transplant
[9], long-term recipients of such an initially rejected graft
rapidly reject a second graft.
This experimental data fits with the clinical observa-
tions gathered on the largest, single-center, second kidney
graft cohort analyzed. Data concerning this cohort of pa-
tients have been collected in the validated DIVAT data
bank and concern grafts performed in a sufficiently re-
cent and “clinically homogeneous” time period, in which
all recipients received a treatment using a calcineurin in-
hibitor. Interestingly, we confirm a significant relationship
between both a higher level of PRA and the percentage
of immunized patients and the nephrectomy of the first
transplant. However, the fact that the second graft out-
come was similar in the two groups does not suggest that
this low PRA and immunization rate are linked to the
presence of regulatory cells. Rather, a possible absorp-
tion of antibodies onto the first rejected graft, as also
suggested by the study of rejected graft eluates [20], may
be involved. Furthermore, we were unable to confirm that
the presence of the first graft conferred a survival advan-
tage to the second graft. No difference in incidence of AR
or in graft function and daily proteinuria was observed.
Nevertheless, our data do not enable us to definitively
rule out differences between the two groups due to the
need for a very large sample size to accept the statistical
“null hypothesis.” However, despite we cannot rule out
an effect of nephrectomy on the outcome of the second
kidney graft, our data suggest that this effect should be
necessarily small. Despite a high HLA matching policy
and other factors that could affect AR incidence, both
groups were similarly managed, and graft survival was
identical in recipients that had or had not undergone graft
nephrectomy. This higher incidence of immunization is
probably not counterbalancing a possible “hidden” ben-
eficial effect of first graft nephrectomy, since no increase
in vascular rejection episodes or long-term chronic re-
jection (including proteinuria) was observed. Finally, the
stringent HLA matching policy followed in this cohort
should not minimize a potential regulatory effect. On the
contrary, HLA matching (and HLA-DR matching in par-
ticular) tends to correlate with immune regulation after
kidney transplantation [21].
CONCLUSION
Taken collectively, our data obtained both in an exper-
imental model that has been shown to be highly sensitive
to regulatory T-cell modulation, and in a large cohort of
human recipients of a second kidney graft, do not suggest
any beneficial effect of a previous graft rejection or the
presence of the first rejected graft at the time of a subse-
quent transplantation on the outcome of this subsequent
transplant.
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